Stocks · News reference
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ADC Therapeutics SA (ADCT)
Filed: 2026-08-13 AccNo: 0000950103-26-012287 Size: 33 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
ADC Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial